オマタ タク
OMATA Taku
小俣 卓 所属 医学部 医学科(附属八千代医療センター) 職種 准教授 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis. |
掲載誌名 | 正式名:Brain & development 略 称:Brain Dev ISSNコード:18727131/03877604 |
掲載区分 | 国外 |
出版社 | Elsevier B.V. |
巻・号・頁 | 37(8),pp.808-816 |
著者・共著者 | Takafumi Nishimura†, Yuji Inaba*, Yozo Nakazawa, Taku Omata, Manami Akasaka, Ikuko Shirai, Motoki Ichikawa |
発行年月 | 2015/09 |
概要 | OBJECTIVE:Myasthenia gravis (MG) is a T-cell dependent and antibody mediated autoimmune disease. Recent studies of adult patients and animal models have shown that regulatory T cells (Tregs) play an important role in the pathogenesis of MG, but little is known about MG in children. This study evaluated the role of peripheral blood Tregs in childhood ocular MG and assessed if Tregs could be an index for estimating immunological status.PATIENTS AND METHODS:Clinical data and peripheral lymphocytes were obtained from 13 children with serum AChR antibody-positive ocular type MG and 18 age-matched controls. Committed cells from MG patients were divided into two clinical stages: active (n=12) and remission (n=11). Tregs and Th17 cells were analyzed by flow cytometric analysis based on CD4(+)CD25(+) intracellular Foxp3(+) and CD4(+) intracellular IL-17A(+) fractions, respectively.RESULTS:The percentage of Tregs among peripheral blood CD4(+) T cells in active stage, remission stage, and control groups was 3.3±1.3%, 4.8±1.7%, and 5.0±0.6%, respectively. The Treg population was significantly lower in the active stage than in the remission stage and controls. Furthermore, Treg percentage was significantly lower during relapse of myasthenia symptoms. We witnessed no remarkable associations between the percentage of Tregs and immune suppressant dosages.CONCLUSIONS:A significant reduction in the peripheral Treg population is considered to contribute to the pathophysiology of ocular type childhood MG and may be a marker of immunological state in these patients. |
DOI | 10.1016/j.braindev.2014.12.007 |
PMID | 25563663 |